BNET Industries

Market Cap:$151.2B
Last Fiscal Year Sales:$48.4B
- Public
- US
Dow Jones Description
Taking care of you and your four-legged friends too! Pfizer Inc. (NYSE: PFE), based in New York, NY, discovers, develops, manufactures and sells prescription medications for humans and animals. Employing about 115,000 people, this $51.3 billion company operates in three segments: Human Health, Consumer Healthcare and Animal Health. Together, these segments cover treatments for diseases such as cardiovascular and metabolic diseases, medications for oral care, tobacco dependence, and products for prevention and treatment of diseases in livestock and pets.
Number of Employees 81,800
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Pfizer signs development deal with Protalix
-
Pfizer signs agreement with Protalix BioTherapeutics for Taliglucerase alfa
-
Pfizer Inc. PFE JOBS Acquires Rights to Protalix Biotherapeutics's Gaucher Drug in Deal Worth $115M
-
Roche's Merger Formula for Genentech
-
Pfizer PFE Will Not Renew Ethical Distribution Agreement Term with MWI Veterinary Supply MWIV
-
Pfizer Inc. and Wyeth; Analysis of Agreement Containing Consent Order To Aid Public Comment and...
-
A 2nd Loss for Pfizer in Drug Suits
-
Pfizer acquires stem cell therapies assets of Axordia
-
Standpoint Raised Its FY10 Price Target on Pfizer PFE to $24
-
ImmunoVaccine signs exclusive licence deal with Pfizer
-
Pfizer Animal Health selects Bader Rutter as agency of record
-
FDA panel backs Pfizer's anti-infection vaccine for kids
-
Cash Just Kept On Piling Up, But It Looks Like The Spending Has Started
-
Goldman Sachs Said Pfizer PFE Best Positioned US Pharma in China
-
EDITORIAL: Difficult mix of business, science
-
$75M verdict unsealed in Prempro-cancer case
-
Sanofi-Aventis on hunt for Boston partners
-
Pfizer says in partnership deal with BMP in China
-
Pfizer Inc. PFE Says in Partnership Deal with BMP Sunstone in China
-
Still Enjoying Those Acquisitions, Pfizer?
News & Analysis
Filter by
fda and pfizer inc. - All News and Analysis
FDA Offers Pfizer's HIV Drug Selzentry New Life -- For All the Good It Will Do
The FDA approved Pfizer's anti-HIV drug Selzentry for expanded use in combination with other antiretroviral agents for treatment-naïve patients who are infected with only CCR5-tropic HIV-1. Contrary to company expectations, perceived limitations of this entry inhibitor could stall efforts to facilitate usage beyond salvage therapy. by David Phillips
Pfizer Used Docs Accused of Misconduct to Prep Geodon Submission to FDA
Pfizer used three physicians who have since been accused of misconduct to prepare submissions to the FDA for the approval of the antipsychotic Geodon, according to a whistleblower lawsuit brought by a Harrisburg, Pa., doctor. by Jim Edwards
Pfizer - Bextra: DOJ press conference
Justice Department Announces Largest Health Care Fraud Settlement in Its History Pfizer to Pay $2.3 Billion for Fraudulent Marketing WASHINGTON – American pharmaceutical giant Pfizer Inc. and its subsidiary Pharmacia & Upjohn Company Inc. (hereinafter together "Pfizer") have agreed to pay...
Pfizer Exec Says FDA's Lack of Social Media Guidance Is "a Problem"
Pfizer PR chief Ray Kerins blasted the FDA's lack of guidance on social media as "a problem" at a recent conference: "There actually are no guidelines for corporations like Pfizer in what we can and cannot do in social media, and that's a problem." by Jim Edwards
FDA Gives Pfizer's Penis-Straightening Drug Priority Review
The FDA granted priority review status to a drug Pfizer is developing that will cure curvature of the penis. BNET readers first learned about Xiaflex -- and the rather less well publicized fact that it must be administered by injection into the organ itself -- back in December. by Jim...
Document Shows Rogue Bextra Operation Inside Pfizer
The "information" document filed by federal prosecutors against Mary Holloway describes what appears to be a rogue sales unit inside Pfizer dedicated to selling the painkiller Bextra off-label and at unapproved doses. Holloway is believed to be a former Pfizer employee (see Peter Rost's join-the-dots conclusion) although documents in the...
Wyeth v. Levine: A Conflicted Roberts Didn't Recuse Himself; Ruling Encourages Unilateral Label Changes
There are three interesting things about the U.S. Supreme Court's ruling against Wyeth's preemption claim. (The case was about whether the FDA preempts state courts from ruling on drug safety.) First, Chief Justice John Roberts took part in the decision even though he owns Pfizer stock (Pfizer...
Federal Prosecutor Warns Drug Companies on Off-Label Promotion: "This Must Stop''
Laurie Magid, the acting U.S. attorney for Pennsylvania's Eastern District, has written a strongly worded warning to drug companies that they must stop promoting off-label uses for drugs or face the consequences. The warning comes after both Pfizer and Eli Lilly paid record fines for off-label promotion...
FDA Caves to Pfizer, Industry on Antibiotics Ruling
The Food and Drug Administration has quietly withdrawn its order banning extralabel use of the antibiotic cephalosporin, so that it can "fully consider the comments" it has received on the issue. When the agency announced the order on July 3, drug companies and agriculture groups were outraged....
Q&A: Peter Rost on His Quixotic Bid to Become Obama's FDA Chief
Pfizer whistleblower and compulsive blogger Peter Rost has tossed his Panama hat into the ring for the post of FDA commissioner in the new Obama administration. He's got the "backing" -- or at least the paperwork -- of Sen. Sherrod Brown and Rep. Jo Ann Emerson. Rost...
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
